睾酮5-α还原酶Ⅱ基因多态性与影响前列腺癌预后因素关系的研究  

Association of polymorphisms in testosterone 5-alpha-reductase Ⅱ genotype and prognosis factors of prostate cancer.

作　　者：佟明[1] 徐忠[2] 艾军魁[1] 袁亦铭[1] 殷毅[1] 王军起[1] 李宏伟[1] 刘建河[1] 辛殿旗[1] 周利群[1] 李鸣[1] 那彦群[1] 

机构地区：[1]北京大学第一医院泌尿外科,100034 [2]辽宁省鞍山市中心医院泌尿外科

出　　处：《中华外科杂志》2004年第24期1493-1496,共4页Chinese Journal of Surgery

基　　金：国家自然科学基金资助项目(30070755)

摘　　要：目的探讨睾酮5-α还原酶Ⅱ(SRD5A2)基因多态性与影响前列腺癌预后因素的关系。方法对112例前列腺癌患者(前列腺癌组)与89例前列腺增生患者(前列腺增生组)的SRD5A2基因89密码子亮氨酸替代缬氨酸(V89L)及49密码子苏氨酸替代丙氨酸(A49T)多态性位点进行酶切鉴定,了解V89L及A49T基因多态性分布情况的差异,及基因多态性与前列腺癌患者的年龄、血游离前列腺特异抗原(PSA)、总PSA、游离PSA／总PSA值、Gleason评分、临床分期的关系。结果前列腺癌组与前列腺增生组V89L和A49T基因频度风险无显著性差异(分别为0.040与0.045,0.308与0.399,x2值为0.047、3.606,P均>0.05)。前列腺癌组AT+TT基因型患者的发病年龄[(65±9)岁]明显低于AA基因型者[(71±7)岁](P=0.03),Gleason评分平均水平明显高于AA基因型(P=0.015)。VV和VL+LL基因型各评价预后指标差异无显著性。分段评价PSA水平、Gleason评分、临床分期、年龄,均与两种基因型无相关性。结论AT+TT基因型前列腺癌患者的预后可能较差,VL+LL基因型与预后无明显关系。Objective The correlation were studied between testosterone 5-alpha-reductase Ⅱ (SRD5A2) gene polymorphisms and prognosis factors. Methods V89L and A49T variants was identified with Mwo1 and Rsal. The differences of V89L and A49T between cancer of prostate (CaP) and benign prostatic hyperplusia (BPH) were studied. In addition, we also researched the association of polymorphisms with age of onset, free prostate specific antigen(FPSA) , total PSA (TPSA) , FPSA/TPSA(F/T) , Gleason score, and T stage in cancer group. Results We found no differences of V89L and A49T polymorphisms between CaP and BPH. In CaP group the A49T variant was associated with lower age of onset ( P = 0. 03) and higher Gleason score (P = 0. 015 ). There were no differences between VV and VL + LL polymorphisms with any of the characteristics studied. When the characteristics above were regarded as two-level discrete variable , there were no differences by A49T and V89Lvariants. Conclusion In CaP group, the AT + TT genotype was perhaps associated with poor prognosis. VL + LL genotype has no relation with prognosis .

关 键 词：前列腺癌 患者 基因多态性分布 GLEASON评分 预后因素 基因型 睾酮 还原酶 密码子 酶切 

分 类 号：R737.25[医药卫生—肿瘤] R697[医药卫生—临床医学]